Journal of Clinical Endocrinology & Metabolism, Vol 75, 1186-1191, Copyright © 1992 by Endocrine Society

ARTICLES

Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man

I Turkalj, U Keller, R Ninnis, S Vosmeer and W Stauffacher
Department of Internal Medicine, University Hospital, Basel, Switzerland.

The metabolic effects of recombinant human insulin-like growth factor-I (IGF-I) were assessed in five groups of normal male overnight-fasted volunteers receiving infusions of either 0, 5, 7.5, 15, or 30 micrograms/kg.h IGF-I during 8 h, resulting in total plasma IGF-I concentrations 127 +/- 7, 247 +/- 30, 389 +/- 39, 573 +/- 62, 620 +/- 105 ng/ml, respectively. Glucose consumption (euglycemic glucose clamp) increased dose dependently during IGF-I infusion (P < 0.001) up to 6.7 +/- 1.3 mg/kg. min in the 30 micrograms/kg.h group. Plasma triglyceride concentrations decreased with increasing doses of IGF-I (P < 0.03); the fall was 43% in the 30 micrograms/kg.h group. Plasma free fatty acid concentrations decreased during 7.5, 15, and 30 micrograms/kg.h IGF-I by 23%, 34%, and 48%, respectively. IGF-I lowered plasma beta- hydroxybutyrate concentrations in a dose-dependent manner (P < 0.025). Plasma concentrations of leucine and alpha-ketoisocaproate decreased dose dependently (P < 0.001 and P < 0.015). Whole body leucine flux (1- 13C-leucine infusion technique) decreased with increasing doses of IGF- I by 41% during 30 micrograms/kg.h, indicating decreased whole body protein breakdown. Leucine oxidation into 13CO2 decreased with increasing doses of IGF-I (P < 0.045) by 57% in the 30 micrograms/kg.h group, suggesting inhibition of irreversible loss of leucine. Plasma C- peptide and insulin concentrations decreased dose dependently (P < 0.005 and P < 0.02), indicating diminished insulin secretion. Thus, acute elevation of plasma IGF-I concentrations in man results in metabolic effects which are qualitatively similar to those described previously of insulin.

This article has been cited by other articles:

				P. Pennisi, O. Gavrilova, J. Setser-Portas, W. Jou, S. Santopietro, D. Clemmons, S. Yakar, and D. LeRoith Recombinant Human Insulin-Like Growth Factor-I Treatment Inhibits Gluconeogenesis in a Transgenic Mouse Model of Type 2 Diabetes Mellitus Endocrinology, June 1, 2006; 147(6): 2619 - 2630. [Abstract] [Full Text] [PDF]

				M. J. Toth and D. E. Matthews Whole-Body Protein Metabolism in Chronic Heart Failure: Relationship to Anabolic and Catabolic Hormones JPEN J Parenter Enteral Nutr, May 1, 2006; 30(3): 194 - 201. [Abstract] [Full Text] [PDF]

				M. Hansen, R. Morthorst, B. Larsson, A. Flyvbjerg, M. H. Rasmussen, H. Orskov, A. Astrup, M. Kjaer, and K. H. W. Lange Effects of 2 wk of GH administration on 24-h indirect calorimetry in young, healthy, lean men Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1030 - E1038. [Abstract] [Full Text] [PDF]

				M. L. Healy, J. Gibney, D. L. Russell-Jones, C. Pentecost, P. Croos, P. H. Sonksen, and A. M. Umpleby High Dose Growth Hormone Exerts an Anabolic Effect at Rest and during Exercise in Endurance-Trained Athletes J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5221 - 5226. [Abstract] [Full Text] [PDF]

				H. Norrelund, K. S. Nair, S. Nielsen, J. Frystyk, P. Ivarsen, J. O. L. Jorgensen, J. S. Christiansen, and N. Moller The Decisive Role of Free Fatty Acids for Protein Conservation during Fasting in Humans with and without Growth Hormone J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4371 - 4378. [Abstract] [Full Text] [PDF]

				M. S. Boyne, M. Thame, F. I. Bennett, C. Osmond, J. P. Miell, and T. E. Forrester The Relationship among Circulating Insulin-Like Growth Factor (IGF)-I, IGF-Binding Proteins-1 and -2, and Birth Anthropometry: A Prospective Study J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1687 - 1691. [Abstract] [Full Text] [PDF]

				M. M. Buijs, J. A. Romijn, J. Burggraaf, M. L. de Kam, A. F. Cohen, M. Frolich, F. Stellaard, A. E. Meinders, and H. Pijl Growth Hormone Blunts Protein Oxidation and Promotes Protein Turnover to a Similar Extent in Abdominally Obese and Normal-Weight Women J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5668 - 5674. [Abstract] [Full Text] [PDF]

				T. Pratipanawatr, W. Pratipanawatr, C. Rosen, R. Berria, M. Bajaj, K. Cusi, L. Mandarino, S. Kashyap, R. Belfort, and R. A. DeFronzo Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects Am J Physiol Endocrinol Metab, June 1, 2002; 282(6): E1360 - E1368. [Abstract] [Full Text] [PDF]

				H. Norrelund, N. Moller, K. S. Nair, J. S. Christiansen, and J. O. L. Jorgensen Continuation of Growth Hormone (GH) Substitution during Fasting in GH-Deficient Patients Decreases Urea Excretion and Conserves Protein Synthesis J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3120 - 3129. [Abstract] [Full Text] [PDF]

				V. Y. Hayes, R. J. Urban, J. Jiang, T. J. Marcell, K. Helgeson, and N. Mauras Recombinant Human Growth Hormone and Recombinant Human Insulin-Like Growth Factor I Diminish the Catabolic Effects of Hypogonadism in Man: Metabolic and Molecular Effects J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2211 - 2219. [Abstract] [Full Text]

				A. L. Friedlander, G. E. Butterfield, S. Moynihan, J. Grillo, M. Pollack, L. Holloway, L. Friedman, J. Yesavage, D. Matthias, S. Lee, et al. One Year of Insulin-Like Growth Factor I Treatment Does Not Affect Bone Density, Body Composition, or Psychological Measures in Postmenopausal Women J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1496 - 1503. [Abstract] [Full Text]

				H. Nørrelund, K. S. Nair, J. O. L. Jørgensen, J. S. Christiansen, and N. Møller The Protein-Retaining Effects of Growth Hormone During Fasting Involve Inhibition of Muscle-Protein Breakdown Diabetes, January 1, 2001; 50(1): 96 - 104. [Abstract] [Full Text]

				N. Mauras, V. Martinez, A. Rini, and J. Guevara-Aguirre Recombinant Human Insulin-Like Growth Factor I Has Significant Anabolic Effects in Adults with Growth Hormone Receptor Deficiency: Studies on Protein, Glucose, and Lipid Metabolism J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3036 - 3042. [Abstract] [Full Text]

				K. Cusi and R. DeFronzo Recombinant Human Insulin-Like Growth Factor I Treatment for 1 Week Improves Metabolic Control in Type 2 Diabetes by Ameliorating Hepatic and Muscle Insulin Resistance J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3077 - 3084. [Abstract] [Full Text]

				E. A. Liechty, D. W. Boyle, H. Moorehead, W.-H. Lee, X.-L. Yang, and S. C. Denne Glucose and amino acid kinetic response to graded infusion of rhIGF-I in the late gestation ovine fetus Am J Physiol Endocrinol Metab, September 1, 1999; 277(3): E537 - E543. [Abstract] [Full Text] [PDF]

				A. F. Tarantal, M. K. Hunter, and S. E. Gargosky Direct Administration of Insulin-Like Growth Factor to Fetal Rhesus Monkeys (Macaca mulatta) Endocrinology, August 1, 1997; 138(8): 3349 - 3358. [Abstract] [Full Text] [PDF]

				S. B. Bowes, M. Umpleby, M. H. Cummings, N. C. Jackson, P. V. Carroll, C. Lowy, P. H. Sonksen, and D. L. Russell-Jones The Effect of Recombinant Human Growth Hormone on Glucose and Leucine Metabolism in Cushing's Syndrome J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 243 - 246. [Abstract] [Full Text] [PDF]